Chronic Pain Market to Reach US$ 28.5 Billion by 2033, at CAGR of 3.01% from 2023 to 2033

How big is the chronic pain market?

The 7 major chronic pain markets reached a value of US$ 20.6 Billion in 2022. Looking forward, IMARC Group expects the 7MM to reach US$ 28.5 Billion by 2033, exhibiting a growth rate (CAGR) of 3.01% during 2023-2033.

The report offers a comprehensive analysis of the chronic pain market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the chronic pain market.

Request a PDF Sample of the Report: https://www.imarcgroup.com/chronic-pain-market/requestsample

Chronic pain is a pervasive health issue affecting millions of individuals worldwide and having a profound impact on their quality of life. The chronic pain market has been driven by various factors, making it a dynamic and evolving sector of the healthcare industry. The demographic shift towards an aging population is contributing to the growth of the market. As people age, they are more likely to develop chronic pain conditions such as osteoarthritis, lower back pain, arthritis, migraines, neuropathic pain, etc. The prevalence of chronic pain conditions is on the rise, which has created a consistent demand for pain management solutions. Technological advancements and research in pain management have led to the development of innovative treatments. This includes minimally invasive procedures, targeted drug therapies, and neurostimulation techniques. Pharmaceutical companies are extensively investing in the development of novel pain medications, such as non-opioid analgesics and abuse-deterrent formulations. These innovations aim to provide effective pain relief while minimizing the risk of addiction. Increased awareness of the condition and its impact on individuals has spurred greater efforts in pain education and advocacy. This has resulted in more people seeking medical care and treatment for their chronic pain. 

Governments and regulatory authorities have taken steps to address the opioid epidemic by implementing stricter regulations and promoting non-opioid alternatives for pain management. These initiatives have shaped the landscape of the market. The COVID-19 pandemic augmented the adoption of telehealth services and remote monitoring for chronic pain patients. Such technologies have improved patient access to healthcare professionals and reduced the need for in-person appointments. Moreover, complementary and alternative therapies, including acupuncture, yoga, and mindfulness-based stress reduction, have gained popularity in the management of chronic pain. These options are anticipated to propel the growth of the chronic pain market in the coming years.

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic pain market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic pain market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current chronic pain marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape With Key Players:

The competitive landscape of the chronic pain market has been studied in the report with the detailed profiles of the key players operating in the market.

Some Key Players:

Pfizer
Biodelivery Sciences
Astrazeneca
Purdue Pharma

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=6612&flag=C

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Contact Us:

IMARC Group
134 N 4th St
Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.